Table 4.
Proportion of patients achieving ≥ 0.5-point reductions in ACQ-5 score, by baseline characteristics
| Mepolizumab | Placebo | ||
|---|---|---|---|
| ITT population | |||
| Patients with ≥ 0.5-point reduction in ACQ-5 score, n (%) | 272/465 (58) | 201/462 (44) | |
| Odds ratio (mepolizumab/placebo), 95% CI; p-value | 1.91 (1.45, 2.52); p < 0.001 | ||
| Age at asthma onset: < 18 years | |||
| Patients with ≥ 0.5-point reduction in ACQ-5 score, n/N (%) | 78/132 (59) | 50/119 (42) | |
| Odds ratio (mepolizumab/placebo), 95% CI | 1.84 (1.06, 3.20) | ||
| Age at asthma onset: 18–< 40 years | |||
| Patients with ≥ 0.5-point reduction in ACQ-5 score, n/N (%) | 93/172 (54) | 69/171 (40) | |
| Odds ratio (mepolizumab/placebo), 95% CI | 1.93 (1.20, 3.12) | ||
| Age at asthma onset: ≥ 40 years | |||
| Patients with ≥ 0.5-point reduction in ACQ-5 score, n/N (%) | 100/160 (63) | 82/172 (48) | |
| Odds ratio (mepolizumab/placebo), 95% CI | 2.27 (1.39, 3.70) | ||
| Lung function: ≤ 60% predicted FEV1 | |||
| Patients with ≥ 0.5-point reduction in ACQ-5 score, n/N (%) | 149/243 (61) | 95/238 (40) | |
| Odds ratio (mepolizumab/placebo), 95% CI | 2.53 (1.73, 3.71) | ||
| Lung function: > 60–80% predicted FEV1 | |||
| Patients with ≥ 0.5-point reduction in ACQ-5 score, n/N (%) | 101/176 (57) | 86/177 (49) | |
| Odds ratio (mepolizumab/placebo), 95% CI | 1.40 (0.87, 2.24) | ||
| Lung function: ≥ 80% predicted FEV1 | |||
| Patients with ≥ 0.5-point reduction in ACQ-5 score, n/N (%) | 22/46 (48) | 20/47 (43) | |
| Odds ratio (mepolizumab/placebo), 95% CI | 1.45 (0.47, 4.48) | ||
ACQ Asthma Control Questionnaire, CI confidence interval, FEV1 forced expiratory volume in 1 s, ITT intent-to-treat